| Autor: |
Anne Keating, Bruce D. Cheson, Amanda L. Seiz, Andres Lopez-Hernandez, Nancy L. Bartlett, Setareh Shamsili, Julie M. Vose |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Cancer. 118:3128-3134 |
| ISSN: |
0008-543X |
| DOI: |
10.1002/cncr.26510 |
| Popis: |
BACKGROUND: Few effective therapeutic options exist for patients with refractory diffuse large B-cell lymphoma (DLBCL). YM155 is a survivin suppressant with activity against DLBCL in a phase I trial. This phase II study was conducted to better characterize the toxicity and efficacy of this small molecule in patients with refractory DLBCL. METHODS: Forty-one patients with a median age of 66 years and 3 prior regimens were enrolled and treated with a YM155 dose of 5 mg/m2/d by continuous infusion for 168 hours every 21 days for up to 15 cycles of treatment. The median number of completed cycles was 3. RESULTS: One patient had a complete remission (CR) (2.4%) with an additional 2 patients (5.9%) responding, with a median progression-free survival of 58 days. CONCLUSIONS: YM155 was well tolerated with major toxicities including anemia and fatigue. Whereas YM155 had limited single-agent activity, preclinical data suggest its role in combination with other agents, including rituximab, and a study of that combination in ongoing. Cancer 2012;118: 3128–34. © 2011 American Cancer Society. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text